p53

Scientific explanation

TP53 encodes a stress-responsive factor controlling cell-cycle arrest, and metabolic adaptation. Loss or mutation is among the most common cancer events.

Cancers where relevant

Breast cancer Triple-negative breast cancer Lung cancer Small-cell lung cancer Colorectal cancer Gastric cancer Esophageal cancer Ovarian cancer Cervical cancer Endometrial cancer Uterine cancer Neuroendocrine prostate cancer Bladder cancer Testicular cancer Brain tumors Glioblastoma IDH-mutant glioma IDH-wildtype glioma MGMT-methylated glioma Skin cancers Head and neck cancers Thyroid cancer Neuroendocrine tumors Bone cancers

Compounds that intersect this pathway

Mebendazole

Benzimidazole that binds β-. Mammalian disruption, mitotic arrest and related signalling in cancer models are preclinical and are not an approved anticancer use.

Evidence in mapped cancers: In Vitro · In Vivo · Mechanistically Plausible

Fenbendazole

Veterinary benzimidazole with and experimental glucose-transport effects in cell models. Not an established human antineoplastic.

Convergence partners

Other pathways that co-occur with p53 on mapped adjunct records: Apoptosis.

This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.